Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms

 Sarepta Therapeutics, Inc.  (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will share new data from across its genetic medicine portfolio at the 27^th International Hybrid Annual Congress of the World Muscle Society 2022 Congress (WMS 2022), taking place Oct. 11-15, 2022, in Halifax, Nova Scotia, Canada.

Data includes a late-breaking real-world evidence presentation on eteplirsen in treated patients with Duchenne amenable to exon 51 skipping, in addition to research from the Company’s gene therapy platform including preclinical data supporting the functionality of the SRP-9001 (delandistrogene moxeparvovec) Sarepta’s investigational gene therapy for the treatment of Duchenne.

https://www.biospace.com/article/releases/sarepta-therapeutics-presents-new-data-from-its-gene-therapy-and-rna-platforms-at-world-muscle-society-2022/